Business Standard

Sunday, January 05, 2025 | 01:55 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Warning Letter for Pithampur SEZ facility remains an overhang for Cipla

While some brokerages believe that the issue could escalate and be detrimental for Cipla, others believe that the Warning Letter was on expected lines and the impact may not be meaningful

Cipla plans acquisitions to take top spot in South Africa drug market
Premium

Ram Prasad Sahu

Listen to This Article

After falling 8 per cent from highs due to downgrades on account of the warning letter from US Food and Drug Administration (USFDA) for its Pithampur facility in Madhya Pradesh, Cipla stock has recovered a bit. The company received the letter on November 17 and it followed the official ‘action initiated’ status (which warrants regulatory action) in August 2023. 
 
Brokerages have a mixed view on the impact. While some brokerages believe that the issue could escalate and be detrimental for Cipla, others believe that the warning letter was on expected lines and the impact may not be meaningful.

B&K Securities believes

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in